Exclusive Summary

• Top-tier compliance and entry advantage: Supported by dual US-FDA and EU-EMA GMP certifications, enabling direct access to highly regulated markets and expedited registration in emerging markets.
• High clinical positioning with massive demand: Addressing a global market of over 200 million osteoporosis patients, it is strictly recommended by international guidelines as a first-line anabolic treatment for patients at extreme high risk of fracture.
• High technical barrier yielding lucrative margins: As a complex peptide injectable, generic competition is globally scarce; combined with Chinese manufacturing cost efficiencies, it offers overseas distributors highly competitive tender pricing and substantial profit margins.